-
Marmur JD, Bullock-Palmer RP, Poludasu S, Cavusoglu E. Avoiding intelligence failures in the cardiac catheterization laboratory: Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention
J Invasive Cardiol. 2009 Dec;21(12):653-64.
-
Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; the RE-COVER Study Group. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism.
N Engl J Med. 2009 Dec 6. [Epub ahead of print]
-
Hankey GJ. At last, a RE-LYable alternative to warfarin for atrial fibrillation.
Int J Stroke. 2009 Dec;4(6):454-5.
-
Cohen AT. Prevention of postoperative venous thromboembolism.
BMJ. 2009 Dec 3;339:b4477. (Comment on: Sweetland et al)
-
Ramacciotti E, Myers DD Jr, Wrobleski SK, Deatrick KB, Londy FJ, Rectenwald JE, Henke PK, Schaub RG, Wakefield TW. P-selectin/ PSGL-1 Inhibitors versus enoxaparin in the resolution of venous thrombosis: A meta-analysis.
Thromb Res. 2009 Dec 3. [Epub ahead of print]